Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Imagine having increased muscle weakness for two years before figuring out the cause. That is the shared experience of myasthenia gravis patients. Canadian startup Decipher MedTech is developing a ...

Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...

What is Decipher Test for Prostate Cancer? Decipher test is a transformative genomic test that evaluates the activity of genes in prostate cancer that has a high chance of progressing to advanced ...

Q: Which doctor should I consult for a Decipher test For Prostate Cancer? A: Decipher test is a transformative genomic test that evaluates the activity of genes in prostate cancer that has a high ...

MR software provider FocusVision has enhanced its Decipher survey platform with the addition of several new capabilities, including the ability to upload a Microsoft Word questionnaire straight into ...

CEO Marc A. Stapley stated that "We delivered 14% revenue growth year-over-year with total revenue of $130 million." He cited testing revenue growth of 14% year-over-year and highlighted continued ...